This guideline has been externally peer-reviewed. This article is simultaneously published in Fertility and Sterility and Human Reproduction. This international PCOS guideline provides clinicians with clear advice on best practices based on available evidence, expert multidisciplinary input, and consumer preferences, supported by a comprehensive translation program. 
| WHAT DOE S THIS ME AN FOR ADOLE SCENTS AND WOMEN WITH P COS?
This guideline aims to optimize evidence-based, consistent care evidence synthesis. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation and ultimately recommendation strength.
Participants/Materials, Setting, Methods: Governance included a six continent international advisory and a project board, five guideline development groups (GDGs), and consumer and translation committees. Extensive health professional and consumer engagement informed guideline scope and priorities. Engaged international societynominated panels included pediatrics, endocrinology, gynecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, public health and other experts, alongside consumers, project management, evidence synthesis, and translation experts. Thirty-seven societies and organizations covering 71 countries engaged in the process. Twenty face-to-face meetings over 15 months addressed 60 prioritized clinical questions involving 40 systematic and 20 narrative reviews. Evidence-based recommendations were developed and approved via consensus voting within the five guideline panels, modified based on international feedback and peer review, with final recommendations approved across all panels. 
Main Results and the

Limitations, Reasons for Caution:
Overall evidence is generally low to moderate quality, requiring significantly greater research in this neglected, yet common condition, especially around refining specific diagnostic features in PCOS. Regional health system variation is acknowledged and a process for guideline and translation resource adaptation is provided.
Wider Implications of the Findings:
The international guideline for the assessment and management of PCOS provides clinicians with clear advice on best practice based on the best available evidence, expert multidisciplinary input and consumer preferences. Research recommendations have been generated and a comprehensive multifaceted dissemination and translation program supports the guideline with an integrated evaluation program.
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| INTRODUC TI ON
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting reproductive aged women, with a prevalence of between 8% to 13% depending on the population studied and definitions used. 
| MATERIAL S AND ME THODS
Best practice evidence-based guideline development methods were applied and are detailed in the full guideline and the technical reports and outlined in Figure 1 and available at https://www.monash.
edu/medicine/sphpm/mchri/pcos. 11 The process aligns with all elements of the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool for quality guideline assessment. 12 This involved extensive evidence synthesis and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework covering evidence quality, feasibility, acceptability, cost, implementation, and ultimately recommendation strength. 13 Evidence synthesis methods are outlined in the full guideline and followed best practice. [12] [13] [14] [15] Categories include evidence-based or consensus recommendations with accompanying clinical practice points (Table 1 ).
Terms include "should," "could," and "should not," are informed by the nature of the recommendation (evidence or consensus), the GRADE framework and quality of the evidence and are independent descriptors reflecting the judgement of the multidisciplinary GDG including consumers. They refer to overall interpretation and practical application of the recommendation, balancing benefits and harms. "Should" is used where benefits of the recommendation exceed harms, and where the recommendation can be trusted to guide practice. "Could" is used where either the quality of evidence was limited or the available studies demonstrate little Quality of the evidence is categorized according to: the number and design of studies addressing the outcome; judgments about the quality of the studies and/or synthesized evidence, such as risk of bias, inconsistency, indirectness, imprecision, and any other considerations that may influence the quality of the evidence; key statistical data; and classification of the importance of the outcomes (Table 2 ). The quality of evidence reflects the extent of confidence in an estimate of the effect to support a particular recommendation 4 and was largely determined by the expert evidence synthesis team.
Grading of Recommendations, Assessment, Development, and Evaluation acknowledges that evidence quality is a continuum; any discrete categorization involves a degree of arbitrariness. Nevertheless, advantages of simplicity, transparency, and vividness outweigh these limitations. 
| RE SULTS
The recommendation table (Table 3) (Table 3) .
This summary, the full guideline and technical reports are supported by a comprehensive co-designed translation program to optimize dissemination and impact with resources freely available at https:// www.monash.edu/medicine/sphpm/mchri/pcos. 
| D ISCUSS I ON
GRADE and quality
CCR
The Ludwig visual score is preferred for assessing the degree and distribution of alopecia **** CPP There are no universally accepted visual assessments for evaluating acne CPP The prevalence of hirsutism is the same across ethnicities, yet the mFG cut-off scores for defining hirsutism and the severity of hirsutism varies by ethnicity -CPP As ethnic variation in vellus hair density is notable, over-estimation of hirsutism may occur if vellus hair is confused with terminal hair; only terminal hairs need to be considered in pathological hirsutism, with terminal hairs clinically growing >5 mm in length if untreated, varying in shape and texture and generally being pigmented -Ultrasound and polycystic ovarian morphology (PCOM) CCR Ultrasound should not be used for the diagnosis of PCOS in those with a gynecological age of <8 years (<8 years after menarche), due to the high incidence of multi-follicular ovaries in this life stage ****
The threshold for PCOM should be revised regularly with advancing ultrasound technology, and age-specific cut off values for PCOM should be defined ****
The transvaginal ultrasound approach is preferred in the diagnosis of PCOS, if sexually active and if acceptable to the individual being assessed **** CCR Using endovaginal ultrasound transducers with a frequency bandwidth that includes 8 MHz, the threshold for PCOM on either ovary, a follicle number per ovary of ≥20 and/or an ovarian volume ≥10 ml on either ovary, ensuring no corpora lutea, cysts or dominant follicles are present *** CPP If using older technology, the threshold for PCOM could be an ovarian volume ≥10 ml on either ovary -
CPP
In patients with irregular menstrual cycles and hyperandrogenism, an ovarian ultrasound is not necessary for PCOS diagnosis; however, ultrasound will identify the complete PCOS phenotype -
In transabdominal ultrasound reporting is best focused on ovarian volume with a threshold of ≥10 ml, given the difficulty of reliably assessing follicle number with this approach -CPP Clear protocols are recommended for reporting follicle number per ovary and ovarian volume on ultrasound.
Recommended minimum reporting standards include:
• Last menstrual period.
• Transducer bandwidth frequency.
• Approach/route assessed.
• Total follicle number per ovary measuring 2-9 mm.
• Three dimensions and volume of each ovary.
• Reporting of endometrial thickness and appearance is referred; three-layer endometrial assessment may be useful to screen for endometrial pathology.
• Other ovarian and uterine pathology, as well as ovarian cysts, corpus luteum, dominant follicles ≥10 mm.
-
There is a need for training in careful and meticulous follicle counting per ovary, to improve reporting -Antimüllerian hormone (AMH) EBR Serum AMH levels should not yet be used as an alternative for the detection of PCOM or as a single test for the diagnosis of PCOS *** ⊕⊕○○ CPP There is emerging evidence that with improved standardization of assays and established cut off levels or thresholds based on large scale validation in populations of different ages and ethnicities, AMH assays will be more accurate in the detection of PCOM -Ethnic variation CCR Health professionals should consider ethnic variation in the presentation and manifestations of PCOS, including:
• A relatively mild phenotype in Caucasians.
• Higher body mass index (BMI) in Caucasian women, especially in North America and Australia.
• More severe hirsutism in Middle Eastern, Hispanic, and Mediterranean women.
• Increased central adiposity, insulin resistance, diabetes, metabolic risks, and acanthosis nigricans in South East Asians and Indigenous Australians.
• Lower BMI and milder hirsutism in East Asians.
• Higher BMI and metabolic features in Africans.
Category
Recommendation • In adults from 18 to 64 years, a minimum of 150 min/wk of moderate intensity physical activity or 75 min/week of vigorous intensities or an equivalent combination of both, including muscle strengthening activities on 2 non-consecutive days/week. • In adolescents, at least 60 minutes of moderate to vigorous intensity physical activity/day, including those that strengthen muscle and bone at least 3 times weekly.
GRADE and quality
• Activity be performed in at least 10-minute bouts or around 1000 steps, aiming to achieve at least 30 minutes daily on most days. *** CCR Health professionals should encourage and advise the following for modest weight-loss, prevention of weight-regain and greater health benefits:
• A minimum of 250 min/week of moderate intensity activities or 150 min/week of vigorous intensity or an equivalent combination of both, and muscle strengthening activities involving major muscle groups on two non-consecutive days/week.
• Minimized sedentary, screen, or sitting time. 
Category Recommendation
GRADE and quality
CPP
When assessing weight, related stigma, negative body image and/or low self-esteem need to be considered and assessment needs to be respectful and considerate. Beforehand, explanations on the purpose and how the information will be used and the opportunity for questions and preferences needs to be provided, permission sought and scales and tape measures adequate. Implications of results need to be explained and where this impacts on emotional wellbeing, support provided -CPP Prevention of weight gain, monitoring of weight and encouraging evidence-based and socio-culturally appropriate healthy lifestyle is important in PCOS, particularly from adolescence • The lowest effective estrogen doses (such as 20-30 micrograms of ethinyloestradiol or equivalent), and natural estrogen preparations are preferred, balancing efficacy, metabolic risk profile, side effects, cost and availability.
• The generally limited evidence on effects of COCPs in PCOS needs to be appreciated with practice informed by general population guidelines (WHO Guidelines).
• The relative and absolute contraindications and side effects of COCPs need to be considered and be the subject of individualized discussion.
• PCOS specific risk factors such as high BMI, hyperlipidemia and hypertension need to be considered.
Combined oral contraceptive pills in combination with metformin and/or anti-androgen pharmacological agents
EBR
In combination with the COCP, metformin should be considered in women with PCOS for management of metabolic features where COCP and lifestyle changes do not achieve desired goals 
CPP
Where metformin is prescribed the following need to be considered:
• Adverse effects, including gastrointestinal side-effects that are generally dose dependent and self-limiting, need to be the subject of individualized discussion.
• Starting at a low dose, with 500 mg increments 1-2 weekly and extended release preparations may minimize side effects.
• Metformin use appears safe long-term, based on use in other populations, however ongoing requirement needs to be considered and use may be associated with low vitamin B12 levels • Use is generally off label and health professionals need to inform women and discuss the evidence, possible concerns and side effects. 
Category Recommendation
GRADE and quality
Letrozole EBR Letrozole should be considered first line pharmacological treatment for ovulation induction in women with PCOS with anovulatory infertility and no other infertility factors to improve ovulation, pregnancy and live birth rates **** ⊕⊕○○ CPP Where letrozole is not available or use is not permitted or cost is prohibitive, health professionals can use other ovulation induction agents -CPP Health professionals and women need to be aware that the risk of multiple pregnancy appears to be less with letrozole, compared to clomiphene citrate -Clomiphene citrate and metformin EBR Clomiphene citrate could be used alone in women with PCOS with anovulatory infertility and no other infertility factors to improve ovulation and pregnancy rates *** ⊕○○○ EBR Metformin could be used alone in women with PCOS, with anovulatory infertility and no other infertility factors, to improve ovulation, pregnancy and live birth rates, although women should be informed that there are more effective ovulation induction agents *** ⊕⊕⊕○ EBR Clomiphene citrate could be used in preference, when considering clomiphene citrate or metformin for ovulation induction in women with PCOS who are obese (BMI is ≥30 kg/m 2 ) with anovulatory infertility and no other infertility factors *** ⊕⊕○○ EBR If metformin is being used for ovulation induction in women with PCOS who are obese (BMI ≥30 kg/m 2 ) with anovulatory infertility and no other infertility factors, clomiphene citrate could be added to improve ovulation, pregnancy and live birth rates *** ⊕⊕○○ EBR Clomiphene citrate could be combined with metformin, rather than persisting with clomiphene citrate alone, in women with PCOS who are clomiphene citrate-resistant, with anovulatory infertility and no other infertility factors, to improve ovulation and pregnancy rates *** ⊕⊕○○
CPP
The risk of multiple pregnancies is increased with clomiphene citrate use and therefore monitoring needs to be considered -Gonadotrophins EBR Gonadotrophins could be used as second line pharmacological agents in women with PCOS who have failed first line oral ovulation induction therapy and are anovulatory and infertile, with no other infertility factors *** ⊕⊕○○ EBR Gonadotrophins could be considered as first line treatment, in the presence of ultrasound monitoring, following counselling on cost and potential risk of multiple pregnancy, in women with PCOS with anovulatory infertility and no other infertility factors *** ⊕⊕○○ EBR Gonadotrophins, where available and affordable, should be used in preference to clomiphene citrate combined with metformin therapy for ovulation induction, in women with PCOS with anovulatory infertility, clomiphene citrate-resistance and no other infertility factors, to improve ovulation, pregnancy and live birth rates **** ⊕⊕⊕○
EBR
Gonadotrophins with the addition of metformin could be used rather than gonadotrophin alone, in women with PCOS with anovulatory infertility, clomiphene citrate-resistance and no other infertility factors, to improve ovulation, pregnancy and live birth rates *** ⊕⊕⊕○ EBR Either gonadotrophins or laparoscopic ovarian surgery could be used in women with PCOS with anovulatory infertility, clomiphene citrate-resistance and no other infertility factors, following counselling on benefits and risks of each therapy **** ⊕⊕⊕○ CPP Where gonadotrophins are prescribed, considerations include:
• Cost and availability.
• Expertise required for use in ovulation induction.
• Degree of intensive ultrasound monitoring required.
• Lack of difference in clinical efficacy of available gonadotrophin preparations.
• Low dose gonadotrophin protocols optimize monofollicular development.
• Risk and implications of potential multiple pregnancy.
-CPP Gonadotrophin induced ovulation is only triggered when there are fewer than three mature follicles and needs to be cancelled if there are more than two mature follicles with the patient advised to avoid unprotected intercourse -Anti-obesity pharmacological agents CCR Pharmacological anti-obesity agents should be considered an experimental therapy in women with PCOS for the purpose of improving fertility, with risk to benefit ratios currently too uncertain to advocate this as fertility therapy
Category Recommendation
GRADE and quality
Laparoscopic surgery EBR Laparoscopic ovarian surgery could be second line therapy for women with PCOS, who are clomiphene citrate resistant, with anovulatory infertility and no other infertility factors *** ⊕⊕○○ CCR Laparoscopic ovarian surgery could potentially be offered as first line treatment if laparoscopy is indicated for another reason in women with PCOS with anovulatory infertility and no other infertility factors *** CPP Risks need to be explained to all women with PCOS considering laparoscopic ovarian surgery -
CPP
Where laparoscopic ovarian surgery is to be recommended, the following need to be considered:
• Comparative cost.
• Intra-operative and post-operative risks are higher in women who are overweight and obese.
• There may be a small associated risk of lower ovarian reserve or loss of ovarian function.
• Periadnexal adhesion formation may be an associated risk.
Bariatric surgery CCR Bariatric surgery should be considered an experimental therapy in women with PCOS, for the purpose of having a healthy baby, with risk to benefit ratios currently too uncertain to advocate this as fertility therapy * CPP If bariatric surgery is to be prescribed, the following need to be considered:
• The need for a structured weight management program involving diet, physical activity and interventions to improve psychological, musculoskeletal and cardiovascular health to continue post-operatively.
• Perinatal risks such as small for gestational age, premature delivery, possibly increased infant mortality.
• Potential benefits such as reduced incidence of large for gestational age fetus and gestational diabetes.
• Recommendations for pregnancy avoidance during periods of rapid weight loss and for at least 12 months after bariatric surgery with appropriate contraception.
If pregnancy occurs, the following need to be considered:
• Awareness and preventative management of pre-and post-operative nutritional deficiencies is important, ideally in a specialist interdisciplinary care setting.
• Monitoring of fetal growth during pregnancy.
-
In vitro fertilization (IVF)
CCR
In the absence of an absolute indication for IVF ± intracytoplasmic sperm injection (ICSI), women with PCOS and anovulatory infertility could be offered IVF as third line therapy where first or second line ovulation induction therapies have failed *** CPP In women with anovulatory PCOS, the use of IVF is effective and when elective single embryo transfer is used, multiple pregnancies can be minimized -CPP Women with PCOS undergoing IVF ± ICSI therapy need to be counselled prior to starting treatment including on:
• Availability, cost and convenience.
• Increased risk of ovarian hyperstimulation syndrome.
• Options to reduce the risk of ovarian hyperstimulation. 
GRADE and quality
CPP
In IVF ± ICSI cycles in women with PCOS, consideration needs to be given to an elective freeze of all embryos -EBR Adjunct metformin therapy could be used before and/or during follicle stimulating hormone ovarian stimulation in women with PCOS undergoing a IVF ± ICSI therapy with a GnRH agonist protocol, to improve the clinical pregnancy rate and reduce the risk of OHSS *** ⊕⊕○○ CCR In a GnRH agonist protocol with adjunct metformin therapy, in women with PCOS undergoing IVF ± ICSI treatment, the following could be considered:
• Metformin commencement at the start of GnRH agonist treatment.
• Metformin use at a dose of between 1000 to 2550 mg daily.
• Metformin cessation at the time of the pregnancy test or menses (unless the metformin therapy is otherwise indicated).
• Metformin side-effects (see metformin section in this table) -
In IVF ± ICSI cycles, women with PCOS could be counselled on potential benefits of adjunct metformin in a GnRH antagonist protocol to reduce risk of ovarian hyperstimulation syndrome (see above for metformin therapy considerations).
-CPP The term in vitro maturation (IVM) treatment cycle is applied to "the maturation in vitro of immature cumulus oocyte complexes collected from antral follicles" (encompassing both stimulated and unstimulated cycles, but without the use of a human gonadotrophin trigger) -
CCR
In units with sufficient expertise, IVM could be offered to achieve pregnancy and livebirth rates approaching those of standard IVF ± ICSI treatment without the risk of OHSS for women with PCOS, where an embryo is generated, then vitrified and thawed and transferred in a subsequent cycle ** EBR, Evidence based recommendation; CCR, Clinical consensus recommendation; CPP, Clinical Practice Point. Evidence quality: ⊕⊕⊕⊕ = high quality, ⊕⊕⊕○ = moderate quality, ⊕⊕○○ = low quality and ⊕○○○ = very low quality evidence. **** Strong recommendation for the option, ***Conditional recommendation for the option; **Conditional recommendation for either the option or the comparison; *Conditional recommendation against the option. Note: Off-label prescribing occurs when a drug is prescribed for an indication, a route of administration, or a patient group that is not included in the approved product information document for that drug by the regulatory body. Prescribing off-label is often unavoidable and common, and does not mean that the regulatory body has rejected the indication, but more commonly there has not been a submission to request evaluation of the indication or that patient group for any given drug. GRADE working group. Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines. # Off-label prescribing occurs when a drug is prescribed for an indication, a route of administration, or a patient group that is not included in the approved product information document for that drug by the regulatory body. Prescribing off-label is often unavoidable and common and does not mean that the regulatory body has rejected the indication, more commonly there has not been a submission to request evaluation of the indication or that patient group for any given drug. 
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